A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem.

OBJECTIVE To evaluate the performance of a diagnostic model based on a composite index using clinical and laboratory data, including cardiovascular biomarkers, to help practitioners to differentiate patients with simple steatosis from those with nonalcoholic steatohepatitis (NASH). DESIGN AND METHODS 101 patients with biopsy proven features of nonalcoholic fatty liver disease were included. We investigated the usefulness of 9 biomarkers in predicting the histological disease severity, including routine biochemical tests, C-reactive protein, soluble intercellular adhesion molecule-1 (sICAM-1) and anthropometric evaluation. Receiver operating characteristic (ROC) curves and likelihood ratios (LRs) were used to evaluate the fit of each test. A composite index was calculated as the product of each individual test LR. RESULTS In a model patient who has all positive tests, the post-test probability for NASH would be 99.5%. CONCLUSION The capacity of each individual biomarker to independently predict the disease outcome was lower than a composite index constructed after multiplying the LR for each individual test combined into a "multimarker" score.

[1]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[2]  Dominique Thabut,et al.  The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis , 2005, Comparative hepatology.

[3]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[4]  J. Machan,et al.  Nonalcoholic Fatty Liver Disease in Severely Obese Subjects , 2007, The American Journal of Gastroenterology.

[5]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[6]  S. Sookoian,et al.  Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A Cross-Sectional Comparison With Adult Treatment Panel III Criteria in Nonobese Nondiabetic Subjects , 2008, Diabetes Care.

[7]  Steven P. Larson,et al.  Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[8]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[9]  P. Angulo GI Epidemiology: nonalcoholic fatty liver disease , 2007, Alimentary pharmacology & therapeutics.

[10]  G. Marchesini,et al.  Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease , 2005, Hepatology.

[11]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[12]  G. Musso,et al.  Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? , 2008, Diabetes Care.

[13]  D. Altman,et al.  Diagnostic tests 4: likelihood ratios , 2004, BMJ : British Medical Journal.

[14]  S. Sookoian,et al.  Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. , 2008, Journal of hepatology.

[15]  M. Tsutsumi,et al.  Usefulness of a Combined Evaluation of the Serum Adiponectin Level, HOMA-IR, and Serum Type IV Collagen 7S Level to Predict the Early Stage of Nonalcoholic Steatohepatitis , 2007, The American Journal of Gastroenterology.

[16]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[17]  A. Grant,et al.  Guidelines on the use of liver biopsy in clinical practice , 1999, Gut.

[18]  E. Çakır,et al.  Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non‐alcoholic fatty liver disease , 2005, Journal of gastroenterology and hepatology.

[19]  D. Sackett,et al.  The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.

[20]  G. Targher,et al.  Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. , 2007, Atherosclerosis.